|
Research
GMM+Fisher Vector+SVM vs. Agentic AI: Two Philosophies of Flow Cytometry Automation
AHEAD Medicine's patented GMM→Fisher Vector→SVM pipeline achieves 98% accuracy in AML diagnosis. Flow Monkey's agentic approach reasons through novel panels without retraining. We dissect both architectures to understand where each wins — and where neither is enough.
References
- [1] Patent WO2022056478A2: Automated classification of immunophenotypes in flow cytometry data https://patents.google.com/patent/WO2022056478A2/en
- [2] A machine learning framework for cross-institute standardized analysis of flow cytometry in differentiating AML from non-neoplastic conditions (Wang et al., 2025) PMID: 40403631
- [3] AHEAD Medicine - Cyto-Copilot Platform https://aheadmedicine.com/
- [4] NIST Flow Cytometry Standards Consortium - AHEAD Medicine Participation https://www.nist.gov/programs-projects/nist-flow-cytometry-s...
- [5] AI, agentic models and lab automation for scientific discovery (Frontiers in AI, 2025) https://www.frontiersin.org/journals/artificial-intelligence...
- [6] AHEAD Unveils Panel-Agnostic Automated AML Diagnosis Solution (PRNewswire) https://www.prnewswire.com/news-releases/ahead-unveils-panel...
- [7] AI in flow cytometry: Current applications and future directions (Cytometry B, 2025) PMID: 40985220
- [8] Patent WO2016094720A1: Automated flow cytometry analysis method (NeoGenomics) https://patents.google.com/patent/WO2016094720A1/en